Qiagen NV QGEN
-
New Morningstar Analyst Report for Qiagen NV
We remain cautious as Qiagen continues to face stiff competition within molecular diagnostics.
-
Trading Margins For Growth Isn't Going To Help Becton Dickinson
By Stephen Simpson : Becton Dickinson ( BDX ) has been a single-digit grower for most of the past decade, and that really hasn't seemed to bother anybody. There's nothing wrong with consistent high-quality performance, particularly when accompanied by improving free cash flow conversion. Although
-
More on Qiagen ( QGEN ): Q1 beats consensus estimates across the board. Revenue grew by 12.1% Y/Y on double-digit sales growth in all regions, including top emerging markets. The company notes that its ...
More on Qiagen ( QGEN ): Q1 beats consensus estimates across the board. Revenue grew by 12.1% Y/Y on double-digit sales growth in all regions …
-
Qiagen ( QGEN ): Q1 EPS of $0.23 beats by $0.02. Revenue of $296M (+12.1% Y/Y) beats by $11M. (PR)
Qiagen ( QGEN ): Q1 EPS of $0.23 beats by $0.02 . Revenue of $296M (+12.1% Y/Y) beats by $11M . ( PR ) Post your comment!
-
BBH Market Vectors Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar
… based in the U.S. comprise 96.5% of BBH's assets. The remaining assets are invested in Dutch holding company Qiagen QGEN , which is listed in New York. Suitability Market Vectors Biotech ETF BBH is an exchange-traded fund that offers investors …
-
China Biotech In Review: GSK Explores All Paths To Increase China Presence
By ChinaBio Today : Deals and Financings Abcam [AIM: ABC] a UK maker of protein research tools, will pay $170 million to buy Epitomics, a San Francisco-area company that has developed humanized rabbit monoclonal antibodies for research purposes. Epitomics has an antibody manufacturing facility in
-
Market's Reaction To M&A Possibilities In Sequencing Companies
By Dave Westenberg: On January 24, Roche ( RHHBY.PK ) made an unsolicited offer directly to the shareholders of Illumina ( ILMN ) for $44.50 a share. The stock jumped the next day to around $55 per share. The offer was rejected and a poison pill resulted because of Illumina's advice from Goldman ...
-
Exact Sciences Could Be Exactly What Biotech Investors Need
By Stephen Simpson : Genomic testing has been a mixed blessing for investors thus far. While progress in the lab and clinic has been significant, the investment picture has followed a pretty familiar pattern - huge enthusiasm (and overvaluation) up front, crushing disappointment, and then general
-
Biotech Gets Personal: Long On Qiagen And SPDR S&P Biotech
By Benjamin Shepherd : Afflicted by a wave of patent expirations and several high-profile class-action lawsuits, the pharmaceutical industry has suffered its fair share of ailments in recent years. Accordingly, the S&P 500 Pharmaceuticals Index has returned a paltry 16.5 percent over the past ...
-
5 Solid Biotechs That Have Delivered Positive Earnings Surprises Recently
By Kinetic Investments : By Bert Wilkison Below is a list of five strong biotechs with great future prospects that have delivered positive earnings surprises recently, and are certainly worth a look. 1. Biogen Idec, Inc. ( BIIB ) EPS From Earnings Surprise: $1.50 Biogen Idec uses cutting edge ...